Literature DB >> 24293469

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives.

Loïc Guillevin1, Iain Armstrong, Rino Aldrighetti, Luke S Howard, Henrik Ryftenius, Aryeh Fischer, Sandra Lombardi, Sean Studer, Pisana Ferrari.   

Abstract

Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease. Although there have been important medical advances in PAH management, the search for a cure continues. Despite an increased understanding of the disease, data on the wider effect of PAH on patients and carers, beyond the clinical symptoms, are still limited. In order to explore this, a large-scale international survey investigated four key areas affected by PAH (physical and practical, emotional, social, and information needs) and provides new insight into patients' and carers' experiences of living with the disease. The results from the survey highlight not only the limited ability of patients to carry out everyday tasks, but also the financial impact and social isolation experienced by both patients and carers. The study confirmed that a decline in a patient's World Health Organization functional class, which indicates an increase in clinical severity of the disease, is associated with greater limitations. Results from the survey demonstrate the need for multidisciplinary PAH management and a comprehensive standard of care to assess and improve all aspects of well-being for both patients and carers. In addition, they underline the need for updated PAH guidelines that address these needs.

Entities:  

Mesh:

Year:  2013        PMID: 24293469     DOI: 10.1183/09059180.00005713

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  40 in total

1.  Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report.

Authors:  Chi Yan Wong; Kwok Wai Tsang; Cho Wing Li; Ho Yan Au; Kwok Ying Chan
Journal:  AME Case Rep       Date:  2021-01-25

2.  Brain Structural Changes in Patients with Pulmonary Arterial Hypertension.

Authors:  Bhaswati Roy; Susana Vacas; Luke Ehlert; Kathy McCloy; Rajan Saggar; Rajesh Kumar
Journal:  J Neuroimaging       Date:  2021-02-09       Impact factor: 2.486

3.  Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver survey.

Authors:  Paresh C Giri; Gizelle J Stevens; Jeanette Merrill-Henry; Udochukwu Oyoyo; Vijay P Balasubramanian
Journal:  Pulm Circ       Date:  2021-05-17       Impact factor: 3.017

4.  Perceptions of received information, social support, and coping in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Bodil Ivarsson; Björn Ekmehag; Roger Hesselstrand; Göran Rådegran; Trygve Sjöberg
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2014-10-23

5.  Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.

Authors:  Deborah McCollister; Shannon Shaffer; David B Badesch; Arthur Filusch; Elke Hunsche; René Schüler; Ingela Wiklund; Andrew Peacock
Journal:  Respir Res       Date:  2016-06-14

6.  Improving communication between healthcare providers and pulmonary arterial hypertension patients: a survey of patient preferences.

Authors:  Jacqueline Brewer; Mary Bartlett; David Harris; Christine Hui
Journal:  Pulm Circ       Date:  2021-05-21       Impact factor: 3.017

7.  Quality of life in pulmonary arterial hypertension.

Authors:  M C Post; J J Mager
Journal:  Neth Heart J       Date:  2015-05       Impact factor: 2.380

Review 8.  Depression in pulmonary arterial hypertension and interstitial lung diseases.

Authors:  Sameer Verma; Jose Cardenas-Garcia; Prasanta R Mohapatra; Arunabh Talwar
Journal:  N Am J Med Sci       Date:  2014-06

Review 9.  Depression in pulmonary arterial hypertension: An undertreated comorbidity.

Authors:  Sameer Verma; Sonu Sahni; Vannan K Vijayan; Arunabh Talwar
Journal:  Lung India       Date:  2016 Jan-Feb

10.  Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.

Authors:  Kathryn Coyle; Doug Coyle; Julie Blouin; Karen Lee; Mohammed F Jabr; Khai Tran; Lisa Mielniczuk; John Swiston; Mike Innes
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.